Invention Grant
- Patent Title: GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
-
Application No.: US16637517Application Date: 2018-08-08
-
Publication No.: US11352405B2Publication Date: 2022-06-07
- Inventor: Aimo Kannt , Maximilian Bielohuby , Ralf Elvert , Michael Wagner , Martin Bossart , Torsten Haack , Stephanie Keil , Werner Seiz
- Applicant: SANOFI
- Applicant Address: FR Paris
- Assignee: SANOFI
- Current Assignee: SANOFI
- Current Assignee Address: FR Paris
- Agency: Lathrop GPM LLP
- Agent James H. Velema, Esq.
- Priority: EP17306059 20170809
- International Application: PCT/EP2018/071478 WO 20180808
- International Announcement: WO2019/030268 WO 20190214
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K38/22 ; A61K38/26 ; A61K45/06 ; A61P1/16 ; A61P3/10 ; C07K14/605
Abstract:
The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
Public/Granted literature
- US20200216510A1 GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS Public/Granted day:2020-07-09
Information query
IPC分类:
